Sanofi, Regeneron cut Praluent list price by 60%

Sanofi (Euronext:SAN; NASDAQ:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are dropping the list price of PCSK9 inhibitor Praluent alirocumab by 60% to match the $5,850

Read the full 248 word article

User Sign In